Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes | Zendy

Christian Dworeck | Zendy; Björn Redfors | Zendy; Oskar Angerås | Zendy; Inger Haraldsson | Zendy; Jacob Odenstedt | Zendy; Dan Ioanes | Zendy; Pétur Pétursson | Zendy; Sebastian Völz | Zendy; Jonas Persson | Zendy; Sasha Koul | Zendy; Dimitrios Venetsanos | Zendy; Anders Ulvenstam | Zendy; Robin Hofmann | Zendy; Jens Jensen | Zendy; Per Albertsson | Zendy; Truls Råmunddal | Zendy; Anders Jeppsson | Zendy; David Erlinge | Zendy; Elmir Ömerovic | Zendy

Open Access

Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes

Author(s) -

Christian Dworeck,

Björn Redfors,

Oskar Angerås,

Inger Haraldsson,

Jacob Odenstedt,

Dan Ioanes,

Pétur Pétursson,

Sebastian Völz,

Jonas Persson,

Sasha Koul,

Dimitrios Venetsanos,

Anders Ulvenstam,

Robin Hofmann,

Jens Jensen,

Per Albertsson,

Truls Råmunddal,

Anders Jeppsson,

David Erlinge,

Elmir Ömerovic

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.18735

Subject(s) - percutaneous coronary intervention , medicine , cardiology , p2y12 , acute coronary syndrome , elevation (ballistics) , st segment , st elevation , myocardial infarction , engineering , structural engineering

Key Points Question Is a pretreatment strategy with P2Y12 receptor antagonists associated with better outcomes vs no pretreatment in patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention? Findings This cohort study including 64 857 patients from the Swedish Coronary Angiography and Angioplasty Registry found that pretreatment with P2Y12 receptor antagonists was not associated with improved survival nor a lower risk of stent thrombosis but was associated with increased risk of bleeding. Meaning These findings suggest that pretreatment with P2Y12 receptor antagonists should not be routinely used in non–ST-segment elevation acute coronary syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research